What is Theravance Biopharma's net investment in lease?

Theravance Biopharma (TBPH) reported net investment in lease of $23M in Q1 2026.

How has Theravance Biopharma's net investment in lease changed year-over-year?

Theravance Biopharma's net investment in lease decreased by 16.1% year-over-year, from $27.43M to $23M.

What is the long-term trend for Theravance Biopharma's net investment in lease?

Over 5 years (2020 to 2025), Theravance Biopharma's net investment in lease has grown at a -10.8% compound annual growth rate (CAGR), from $43.26M to $24.37M.

Theravance Biopharma TBPH Net Investment in Lease

Net Investment in Lease at other companies

Zevra Therapeutics, Inc.ZVRA

——

LQD

Liquidia CorporationLQDA

——

Aurinia PharmaceuticalsAUPH

——

PrecigenPGEN

——

Mirum Pharmaceuticals, Inc.MIRM

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Valuation

See full

Market cap$890.32M+67.5%

Enterprise value$642.72M+37.0%

P/E7.8×—

P/S8.1×0.0×

Profitability

See full

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's net investment in lease?: Theravance Biopharma (TBPH) reported net investment in lease of $23M in Q1 2026.
How has Theravance Biopharma's net investment in lease changed year-over-year?: Theravance Biopharma's net investment in lease decreased by 16.1% year-over-year, from $27.43M to $23M.
What is the long-term trend for Theravance Biopharma's net investment in lease?: Over 5 years (2020 to 2025), Theravance Biopharma's net investment in lease has grown at a -10.8% compound annual growth rate (CAGR), from $43.26M to $24.37M.